PA
RIGL icon

Profund Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Profund Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359K Sell
9,174
-7,569
-45% -$233K 0.01% 700
2026
Q1 		$453K Buy
16,743
+863
+5% +$29K 0.02% 584
2025
Q4 		$680K Buy
+15,880
New +$599K 0.02% 457
2014
Q2 		– Sell
-1,020
Closed -$40K – 1596
2014
Q1 		$40K Buy
+1,020
New +$36.4K ﹤0.01% 1581

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Profund Advisors's RIGL Position: Q2 2026 in Review

Profund Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 45% in Q2 2026, selling an estimated $233K and leaving 9,174 shares worth $359K. The position accounts for 0.01% of the portfolio, ranked #700.

Profund Advisors first reported a position in RIGL in Q1 2014 and has held it in 4 quarters since. The position peaked at $680K in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Profund Advisors held 9,174 shares of Rigel Pharmaceuticals worth $359K as of Q2 2026.
  • Profund Advisors sold 7,569 Rigel Pharmaceuticals shares in Q2 2026, an estimated $233K.
  • Rigel Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #700 holding.
  • Profund Advisors first reported a position in Rigel Pharmaceuticals in Q1 2014 and has held it in 4 quarters since.
  • Profund Advisors's Rigel Pharmaceuticals position peaked at $680K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.